Feature | June 11, 2014

GE Healthcare Unveils Upgradeable PET/CT System

June 11, 2014 — GE Healthcare introduced its Discovery IQ PET/CT (positron emission tomography/computed tomography) system at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. The system enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA) and not available for sale in the United States.

Discovery IQ

Physicians not only want the ability to detect smaller lesions, but also the ability to determine earlier whether the patient is responding to current treatment. With high sensitivity up to 22 cps/kBq, the largest axial field-of-view (up to 26 cm) and quantitative SUV measurements, Discovery IQ provides an essential tool to delivering personalized patient care. It enables physicians to see smaller lesions, scan faster with lower dose and improved image quality, read more efficiently, and reach more patients.

“By 2020, it’s estimated that 50 percent of people will develop cancer at some point in their lives, and we also know that currently approximately 70 percent of cancer patients do not respond to their initial chemotherapy treatment,” said Steve Gray, president and CEO of GE Healthcare MICT. “I’m excited to introduce the Discovery IQ to help physicians with their primary mission of delivering the best possible patient outcomes.  And, we’ve focused on designing the system to make it as accessible as possible to more people in more places, to ensure high-performance PET/CT clinical care is available to whomever needs it.”

Some key features include:

  • GE Healthcare’s Q.Clear PET reconstruction technology, providing up to two times improvement in both image quality and quantitation accuracy;
  • A fully scalable system, allowing for the ability to upgrade as department needs change;
  • Availability for the mobile market, enabling the latest technology across both fixed and mobile environments;
  • New platform design and the new LightBurst detector technology, allowing for whole organ imaging via fast scans at low dose to help maximize patient comfort and safety; and
  • Fast electronics and a dual acquisition channel that enables high quantitative accuracy for all clinically relevant tracers.


Q.Clear

The Q.Clear technology is a critical component of Discovery IQ. It delivers, for the first time, no trade-off between image quality and quantitative SUV measurements. By providing two times improvement in both quantitative accuracy and image quality in PET/CT imaging, this innovative new tool provides benefits to physicians across the cancer care continuum from diagnosis, staging and treatment planning, to treatment assessment.

Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. The new Q.Clear technology shows the advantage of full convergence PET imaging with no compromise between quantitation and image quality. 

CortexID Suite

CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans, enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3-D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism and in PET brain amyloid load between a subject’s images and a normal database, which may be the result of brain neurodegeneration.

For more information: www.gehealthcare.com

Related Content

PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging| December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
PET/CT, calcium blockages, heart attack risk, Intermountain study, American Heart Association, AHA Scientific Sessions 2016
News | PET-CT| November 15, 2016
Many people who experience chest pain but don’t have a heart attack breathe a big sigh of relief when a stress test...
PET/CT, atherosclerotic plaque detection, Stanford University

Application of dual-modality optical and PET/CT activity-based probe in experimental carotid inflammation model. Coronal noninvasive PET/CT scans of (A) healthy and (B) diseased mice with and without ligated carotid arteries respectively. Inset images show optical ex vivo florescence imagining of (A) healthy and (B) diseased carotid arteries.  PET/CT and optical images courtesy of Xiaowei Ma, Toshinobu Saito and Nimali Withana.

News | PET-CT| November 01, 2016
Researchers at Stanford University have demonstrated for the first time the use of a dual optical and positron emission...
NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers| October 28, 2016
The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the state of molybdenum-...
Siemens Healthineers, Symbia Intevo SPECT/CT system, xSPECT Quant, RSNA 2016
Technology | SPECT-CT| October 18, 2016
At the 2016 annual meeting of the Radiological Society of North America (RSNA 2016), Siemens Healthineers will showcase...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
GE Healthcare, Discovery MI PET/CT system, FDA clearance, RSNA 2016
Technology | PET-CT| October 05, 2016
GE Healthcare recently announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Discovery MI digital...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging| September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
UltraSPECT, Xpress3.Cardiac, nuclear imaging, RWJPE, New Jersey, Robert Wood Johnson Physician Enterprise
News | SPECT Imaging| July 25, 2016
UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-...
ASNC, SNMMI, PET standard, Pet cardiac imaging, PET nuclear imaging, perfusion imaging

An example of a cardiac PET-CT imaging, should a color coded image of the left ventricle to help assess myocardial perfusion to detect ischemia using a Siemens scanner.

News | Nuclear Imaging| July 19, 2016
 
Overlay Init